Esophageal candidiasis

SCYNEXIS Presents Interim Analysis from FURI at Virtual IDWeek 2021 Showing Favorable Therapeutic Response in Severe Hospital-Based Fungal Infections Treated with Oral Ibrexafungerp

Retrieved on: 
Wednesday, September 29, 2021
OPC, Biotechnology, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SOC, Tablet, Candidiasis, Standard of care, Rifian, UAB, Multiplicity of infection, Infection, NASDAQ, FDA, Canker, EC, Population, IV, Augusta University, Drug of last resort, Medical Mycology, FURI, FACP, IC, VVC, Esophageal candidiasis, University of Alabama, Joint, Fungemia, Interim analysis, University, IA, MPH, Trial of the century, Risk, Wake Forest Baptist Medical Center, Azole, Safety, QIDP, Mycosis, GLOBE, Pharmaceutical industry, Birth control, Paint

The compilation and disease subset analyses are being presented during IDWeek, taking place virtually September 29 October 3, 2021.

Key Points: 
  • The compilation and disease subset analyses are being presented during IDWeek, taking place virtually September 29 October 3, 2021.
  • Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI) Peter G. Pappas, M.D., University of Alabama at Birmingham (UAB)
    Oral Presentation New Findings in Medical Mycology: O-25.
  • Of the 74 patients treated with oral ibrexafungerp 62.1% showed complete or partial response, 24.3% achieved stable disease, 6.8% showed progressive disease, and 5.4% were indeterminate.
  • The presentation highlights a sub-analysis of eight patients with Candida bone and joint infections from the Phase 3 FURI study.

SCYNEXIS to Present Data on Oral Ibrexafungerp at IDWeek 2021 from Interim Analyses of Phase 3 FURI Clinical Trial Showing Therapeutic Response Rates in Patients with Mucocutaneous and Invasive Fungal Infections

Retrieved on: 
Thursday, September 23, 2021
Biotechnology, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Infection, Tablet, UAB, NASDAQ, FDA, IV, Augusta University, Drug of last resort, Medical Mycology, FURI, FACP, IC, VVC, Esophageal candidiasis, University of Alabama, Fungemia, Interim analysis, University, IA, Canker, MPH, Wake Forest Baptist Medical Center, QIDP, Mycosis, GLOBE, Pharmaceutical industry, Paint

The data from these three presentations provide a deeper understanding of ibrexafungerps activity against a broad spectrum of fungal infections caused by Candida species, including azole- and echinocandin-resistant strains.

Key Points: 
  • The data from these three presentations provide a deeper understanding of ibrexafungerps activity against a broad spectrum of fungal infections caused by Candida species, including azole- and echinocandin-resistant strains.
  • We are encouraged by the interim results of the study as we work toward the goal of making ibrexafungerp available to patients with serious fungal infections in the U.S. and around the world.
  • Ibrexafungerp is in late-stage development for multiple indications, including life-threatening fungal infections caused primarily by Candida (including C. auris) and Aspergillus species in hospitalized patients.
  • In addition, late-stage clinical investigation of ibrexafungerp for the prevention of recurrent Vulvovaginal Candidiasis (VVC) and the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing.

Lilly accelerating baricitinib's availability in India following receipt of permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements

Retrieved on: 
Tuesday, May 4, 2021
Animal diseases, Medical specialties, Clinical medicine, HIV/AIDS, Zoonoses, Immune system disorders, Immunology, Opportunistic infection, Histoplasmosis, Candidiasis, Esophageal candidiasis, Cryptococcosis

"We hope that our donations as well as collaborations with other organizations speed access to baricitinib and provide treatment options for these patients.

Key Points: 
  • "We hope that our donations as well as collaborations with other organizations speed access to baricitinib and provide treatment options for these patients.
  • Follow dose adjustments as recommended in the Fact Sheet for Healthcare Providers for patients with abnormal renal, hematological and hepatic laboratory values.
  • Among opportunistic infections, tuberculosis, multidermatomal herpes zoster, esophageal candidiasis, pneumocystosis, acute histoplasmosis, cryptococcosis, cytomegalovirus and BK virus were reported with Olumiant.
  • However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of research, development and commercialization.

Orphan Drug Designation Granted to Rezafungin in EU for the Treatment of Invasive Candidiasis

Retrieved on: 
Tuesday, January 26, 2021
Infectious diseases, Biotechnology, Pharmaceutical, Health, Fungal diseases, Antifungals, Branches of biology, Echinocandins, Infectious diseases, Sepsis, Invasive candidiasis, Caspofungin, Candidiasis, Fungemia, Esophageal candidiasis, Rezafungin, Mundipharma, Cidara Therapeutics

We are proud that patients affected with invasive candidiasis may have an additional treatment option to treat this potentially life-threatening condition.

Key Points: 
  • We are proud that patients affected with invasive candidiasis may have an additional treatment option to treat this potentially life-threatening condition.
  • We look forward to continuing to work closely with our colleagues at Mundipharma to advance rezafungin through late-stage clinical development.
  • Activity of a long-acting echinocandin, rezafungin, and comparator antifungal agents tested against contemporary invasive fungal isolates (SENTRY Program, 2016 to 2018).
  • Rezafungin versus Caspofungin in a Phase 2, Randomized, Double-Blind Study for the Treatment of Candidemia and Invasive Candidiasis- The STRIVE Trial.

Mycovia Pharmaceuticals Completes Successful Pre-NDA Meeting with FDA for Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis

Retrieved on: 
Thursday, November 12, 2020
FDA, Health, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Animal diseases, Infectious diseases, Medical specialties, Candidiasis, Vaginal yeast infection, Fluconazole, VVC, Esophageal candidiasis

Millions of women experience three or more episodes of vulvovaginal candidiasis each year and need new therapeutic options.

Key Points: 
  • Millions of women experience three or more episodes of vulvovaginal candidiasis each year and need new therapeutic options.
  • Oteseconazole is designed to be highly selective, with fewer side effects and improved efficacy over current treatment options, including the current standard of care for vulvovaginal candidiasis, fluconazole.
  • For more information, please visit www.mycovia.com
    Oteseconazole (VT-1161) is a novel, investigational oral therapy in late-stage clinical development for the treatment of recurrent vulvovaginal candidiasis (RVVC).
  • Oteseconazole received FDA Qualified Infectious Disease Product and Fast-Track designations and, if approved, could be the first FDA-approved treatment for RVVC.

Mycovia Pharmaceuticals Announces Peer-Reviewed Publication of Positive Study Results of Oteseconazole for the Treatment of Acute Vulvovaginal Candidiasis

Retrieved on: 
Wednesday, August 26, 2020
Managed care, Other Health, Health, General Health, Women, Pharmaceutical, Other Science, Research, Consumer, Science, Clinical trials, RTT, Animal diseases, Medical specialties, Infectious diseases, Vaginal yeast infection, Candidiasis, Fluconazole, VVC, Cándida, Esophageal candidiasis

Mycovia Pharmaceuticals, Inc. (Mycovia) today announced the publication of results from a Phase 2 clinical study of its oral antifungal product candidate oteseconazole (VT-1161) for the treatment of acute vulvovaginal candidiasis (VVC).

Key Points: 
  • Mycovia Pharmaceuticals, Inc. (Mycovia) today announced the publication of results from a Phase 2 clinical study of its oral antifungal product candidate oteseconazole (VT-1161) for the treatment of acute vulvovaginal candidiasis (VVC).
  • In this study and others, oteseconazole has shown to be safe, and more potent than fluconazole against the Candida species that cause VVC.
  • The Phase 2 study evaluated the efficacy and safety of oteseconazole versus fluconazole in women who experienced a moderate-to-severe acute episode of VVC (n=55).
  • Oteseconazole (VT-1161) is a novel, investigational oral therapy in late-stage clinical development for the treatment of recurrent vulvovaginal candidiasis (RVVC).

ANI Pharmaceuticals Announces Acquisition of Fluconazole Tablets

Retrieved on: 
Monday, July 6, 2020
RTT, Animal diseases, Medical specialties, Infectious diseases, Candidiasis, Esophageal candidiasis, Fluconazole, Vaginal yeast infection, Cándida, Baudette, Minnesota

BAUDETTE, Minn., July 6, 2020 /PRNewswire/ --ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the acquisition of Fluconazole Tablets USP, 50mg, 100mg, 150mg, and 200mg from a private company for $3.0 million.

Key Points: 
  • BAUDETTE, Minn., July 6, 2020 /PRNewswire/ --ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the acquisition of Fluconazole Tablets USP, 50mg, 100mg, 150mg, and 200mg from a private company for $3.0 million.
  • With this acquisition we further advance our strategy of expanding the ANI product portfolio via the Oakville plant.
  • Fluconazole Tablets USP is indicated for the treatment of vaginal candidiasis (vaginal yeast infections due toCandida) and oropharyngeal and esophageal candidiasis.
  • ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.

The candidiasis drugs market will register a CAGR of almost 4% by 2023

Retrieved on: 
Thursday, February 7, 2019
Infectious diseases, Medical specialties, RTT, Candidiasis, Medicine, Antifungal, Oral candidiasis, Esophageal candidiasis

Although the currently available antifungal drugs are killing various species of candidiasis, some fungi can develop the ability to defend these drugs.

Key Points: 
  • Although the currently available antifungal drugs are killing various species of candidiasis, some fungi can develop the ability to defend these drugs.
  • Technavio' s analysts have predicted that the candidiasis drugs market will register a CAGR of almost 4% by 2023.
  • The signs and symptoms of candidiasis are very broad, and they also depend on the type of candidiasis infection.
  • For the detailed list of factors that will drive and challenge the growth of the candidiasis drugs market during the 2019-2023, view our report.

Lilly to Unveil New Data at the Annual European Congress of Rheumatology, Furthering Commitment to Scientific Discovery in Immunology

Retrieved on: 
Monday, June 11, 2018
HIV/AIDS, Medicine, Health, Immunology, Opportunistic infection, Esophageal candidiasis, Cryptococcosis, Candidiasis, WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents, AIDS-defining clinical condition

"We are excited to be sharing data evaluating baricitinib as a potential treatment for systemic lupus erythematosus, underscoring the potential of our immunology portfolio."

Key Points: 
  • "We are excited to be sharing data evaluating baricitinib as a potential treatment for systemic lupus erythematosus, underscoring the potential of our immunology portfolio."
  • Carefully consider the risks and benefits of OLUMIANT prior to initiating therapy in patients with chronic or recurrent infection.
  • Among opportunistic infections, tuberculosis, multidermatomal herpes zoster, esophageal candidiasis, pneumocystosis, acute histoplasmosis, cryptococcosis, cytomegalovirus, and BK virus were reported with OLUMIANT.
  • Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world.